| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
| FORM 8-K |
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported) January 12, 2006
| PLURISTEM LIFE SYSTEMS, INC. (Exact name of registrant as specified in its charter) |
Nevada
(State or other jurisdiction of incorporation)
001-31392
(Commission File Number)
98-0351734
(IRS Employer Identification No.)
MATAM
Advanced Technology Park, Building No. 20, Haifa, Israel
31905
(Address of principal executive offices and Zip Code)
011-972-4-850-1080
Registrant's telephone number, including area
code
Not
Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
| Item 7.01 Regulation FD Disclosure |
On January 12, 2006, the Registrant announced that it has formulated a cell graft to provide an efficient alternative to the standard procedure of bone marrow transplantation. The cell graft is presently in pre-clinical trials.
| Item 9.01 Financial Statements and Exhibits | |
|
|
News Release dated January 12, 2006. |
| - 2 - |
| SIGNATURES |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PLURISTEM LIFE SYSTEMS,
INC. |
| /s/ Zami
Aberman Zami Aberman Chief Executive Officer Date: January 12, 2006 |